The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib (Lazcluze) as a first-line option for adults with previously untreated advanced non ...
Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
Treatment pattern and outcomes in patients with uncommon or compound EGFR mutations in India: CRSF 2020-03 study. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...
The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...
Overcoming drug resistance with EAI-432, an allosteric EGFR inhibitor for non-small cell lung cancer
EAI-432, an allosteric inhibitor, offers a new approach to targeting mutant-EGFR driven NSCLC By binding outside the ATP pocket, it co-binds with the current standard-of-care third generation EGFR ...
Effect of IKKϵ knock-down on prostate cancer xenograft growth. Background: Activating EGFR mutations have become a backbone in the therapy alogrithm for NSCLC as mutations predict significantly better ...
In a recent study published in Micromachines, researchers assessed the efficiency of a genetic decoding system for diagnosing non-small cell lung cancer (NSCLC). Study: Intelligent Genetic Decoding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback